Literature DB >> 33144490

Classical Drug Digitoxin Inhibits Influenza Cytokine Storm, With Implications for Covid-19 Therapy.

Bette S Pollard1, Jorge C BLANCOl2, John R Pollard3.   

Abstract

BACKGROUND/AIM: Influenza viruses, corona viruses and related pneumotropic viruses cause sickness and death partly by inducing cytokine storm, a hyper-proinflammatory host response by immune cells and cytokines in the host airway. Based on our in vivo experience with digitoxin as an inhibitor of TNFα-driven NFĸB signaling for cytokine expression in prostate cancer in rats and in cystic fibrosis in humans, we hypothesize that this drug will also block a virally-activated cytokine storm. Materials
Methods: Digitoxin was administered intraperitoneally to cotton rats, followed by intranasal infection with 107TCID50/100 g of cotton rat with influenza strain A/Wuhan/H3N2/359/95. Daily digitoxin treatment continued until harvest on day 4 of the experiment.
RESULTS: The cardiac glycoside digitoxin significantly and differentially suppressed levels of the cytokines TNFα, GRO/KC, MIP2, MCP1, and IFNγ, in the cotton rat lung in the presence of influenza virus.
CONCLUSION: Since cytokine storm is a host response, we suggest that digitoxin may have a therapeutic potential not only for influenza and but also for coronavirus infections. Copyright
© 2020, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  COVID-19; GRO/KC; IFNγ; MCP1; MIP-2; RNA-virus; SARS; TNFα; Virus; cardiac glycosides; coronavirus; cytokine storm; digitoxin; digoxin; inflammation; influenza; oleandrin; ouabain

Mesh:

Substances:

Year:  2020        PMID: 33144490      PMCID: PMC7811644          DOI: 10.21873/invivo.12221

Source DB:  PubMed          Journal:  In Vivo        ISSN: 0258-851X            Impact factor:   2.155


  44 in total

Review 1.  Into the eye of the cytokine storm.

Authors:  Jennifer R Tisoncik; Marcus J Korth; Cameron P Simmons; Jeremy Farrar; Thomas R Martin; Michael G Katze
Journal:  Microbiol Mol Biol Rev       Date:  2012-03       Impact factor: 11.056

Review 2.  Airway epithelial cells, cytokines, and pollutants.

Authors:  P R Mills; R J Davies; J L Devalia
Journal:  Am J Respir Crit Care Med       Date:  1999-11       Impact factor: 21.405

3.  Chloroquine inhibits HMGB1 inflammatory signaling and protects mice from lethal sepsis.

Authors:  Minghua Yang; Lizhi Cao; Min Xie; Yan Yu; Rui Kang; Liangchun Yang; Mingyi Zhao; Daolin Tang
Journal:  Biochem Pharmacol       Date:  2013-05-22       Impact factor: 5.858

4.  Protection of ferrets from pulmonary injury due to H1N1 2009 influenza virus infection: immunopathology tractable by sphingosine-1-phosphate 1 receptor agonist therapy.

Authors:  John R Teijaro; Kevin B Walsh; James P Long; Kevin P Tordoff; Gregory V Stark; Amie J Eisfeld; Yoshihiro Kawaoka; Hugh Rosen; Michael B A Oldstone
Journal:  Virology       Date:  2014-01-31       Impact factor: 3.616

Review 5.  Metabolic Regulation of Natural Killer Cell IFN-γ Production.

Authors:  Annelise Y Mah; Megan A Cooper
Journal:  Crit Rev Immunol       Date:  2016       Impact factor: 2.214

6.  NF-kappaB-dependent induction of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and Fas/FasL is crucial for efficient influenza virus propagation.

Authors:  Walter J Wurzer; Christina Ehrhardt; Stephan Pleschka; Friederike Berberich-Siebelt; Thorsten Wolff; Henning Walczak; Oliver Planz; Stephan Ludwig
Journal:  J Biol Chem       Date:  2004-05-12       Impact factor: 5.157

7.  Digitoxin mimics gene therapy with CFTR and suppresses hypersecretion of IL-8 from cystic fibrosis lung epithelial cells.

Authors:  Meera Srivastava; Ofer Eidelman; Jian Zhang; Cloud Paweletz; Hung Caohuy; QingFeng Yang; Kenneth A Jacobson; Eliahu Heldman; Wei Huang; Catherine Jozwik; Bette S Pollard; Harvey B Pollard
Journal:  Proc Natl Acad Sci U S A       Date:  2004-05-10       Impact factor: 11.205

8.  Cirsimaritin inhibits influenza A virus replication by downregulating the NF-κB signal transduction pathway.

Authors:  Haiyan Yan; Huiqiang Wang; Linlin Ma; Xueping Ma; Jinqiu Yin; Shuo Wu; Hua Huang; Yuhuan Li
Journal:  Virol J       Date:  2018-05-21       Impact factor: 4.099

9.  Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.

Authors:  Chaolin Huang; Yeming Wang; Xingwang Li; Lili Ren; Jianping Zhao; Yi Hu; Li Zhang; Guohui Fan; Jiuyang Xu; Xiaoying Gu; Zhenshun Cheng; Ting Yu; Jiaan Xia; Yuan Wei; Wenjuan Wu; Xuelei Xie; Wen Yin; Hui Li; Min Liu; Yan Xiao; Hong Gao; Li Guo; Jungang Xie; Guangfa Wang; Rongmeng Jiang; Zhancheng Gao; Qi Jin; Jianwei Wang; Bin Cao
Journal:  Lancet       Date:  2020-01-24       Impact factor: 79.321

Review 10.  The Antiviral Effects of Na,K-ATPase Inhibition: A Minireview.

Authors:  Luciano Amarelle; Emilia Lecuona
Journal:  Int J Mol Sci       Date:  2018-07-24       Impact factor: 5.923

View more
  9 in total

Review 1.  Nanoscale Technologies in the Fight against COVID-19: From Innovative Nanomaterials to Computer-Aided Discovery of Potential Antiviral Plant-Derived Drugs.

Authors:  Nunzio Iraci; Carmelo Corsaro; Salvatore V Giofrè; Giulia Neri; Angela Maria Mezzasalma; Martina Vacalebre; Antonio Speciale; Antonina Saija; Francesco Cimino; Enza Fazio
Journal:  Biomolecules       Date:  2022-07-30

2.  Selection of the Appropriate Control Group Is Essential in Evaluating the Cytokine Storm in COVID-19.

Authors:  Alice G Vassiliou; Ioanna Dimopoulou; Edison Jahaj; Chrysi Keskinidou; Zafeiria Mastora; Stylianos E Orfanos; Anastasia Kotanidou
Journal:  In Vivo       Date:  2021 Mar-Apr       Impact factor: 2.155

Review 3.  Leveraging knowledge of Asian herbal medicine and its active compounds as COVID-19 treatment and prevention.

Authors:  Desy Liana; Anuchit Phanumartwiwath
Journal:  J Nat Med       Date:  2021-10-08       Impact factor: 3.192

4.  Synthesis and Biological Evaluation of Novel Bufalin Derivatives.

Authors:  VishnuPriya Sampath; Noa Horesh; Ben Sasi; Hiba Zannadeh; Ilana Pogodin; Shiv Vardan Singh; Joseph Deutsch; David Lichtstein
Journal:  Int J Mol Sci       Date:  2022-04-04       Impact factor: 5.923

5.  Development of a new ultra-high-performance liquid chromatography-tandem mass spectrometry method for the determination of digoxin and digitoxin in plasma: Comparison with a clinical immunoassay.

Authors:  Marco Ballotari; Francesco Taus; Giulia Tolle; Elisa Danese; Romolo M Dorizzi; Franco Tagliaro; Rossella Gottardo
Journal:  Electrophoresis       Date:  2022-02-17       Impact factor: 3.595

6.  Analyzing the Systems Biology Effects of COVID-19 mRNA Vaccines to Assess Their Safety and Putative Side Effects.

Authors:  Rima Hajjo; Dima A Sabbah; Alexander Tropsha
Journal:  Pathogens       Date:  2022-06-29

7.  Predicting COVID-19-Comorbidity Pathway Crosstalk-Based Targets and Drugs: Towards Personalized COVID-19 Management.

Authors:  Debmalya Barh; Alaa A Aljabali; Murtaza M Tambuwala; Sandeep Tiwari; Ángel Serrano-Aroca; Khalid J Alzahrani; Bruno Silva Andrade; Vasco Azevedo; Nirmal Kumar Ganguly; Kenneth Lundstrom
Journal:  Biomedicines       Date:  2021-05-17

8.  Cardiac Glycoside Ouabain Exerts Anticancer Activity via Downregulation of STAT3.

Authors:  Jie Du; Lijun Jiang; Fuqiang Chen; Huantao Hu; Meijuan Zhou
Journal:  Front Oncol       Date:  2021-06-30       Impact factor: 6.244

9.  A Case-Control of Patients with COVID-19 to Explore the Association of Previous Hospitalisation Use of Medication on the Mortality of COVID-19 Disease: A Propensity Score Matching Analysis.

Authors:  Jaime Monserrat Villatoro; Gina Mejía-Abril; Lucía Díaz García; Pablo Zubiaur; María Jiménez González; Guillermo Fernandez Jimenez; Inés Cancio; José Ramón Arribas; Carmen Suarez Fernández; Jesús Mingorance; Julio García Rodríguez; José Ramón Villagrasa Ferrer; Antonio J Carcas; Jesús Frías; Francisco Abad-Santos; Alberto M Borobia; Elena Ramírez
Journal:  Pharmaceuticals (Basel)       Date:  2022-01-08
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.